| Literature DB >> 33792888 |
Riccardo Pravisani1, Paolo De Simone2, Damiano Patrono3, Andrea Lauterio4, Matteo Cescon5, Enrico Gringeri6, Michele Colledan7, Fabrizio Di Benedetto8, Fabrizio di Francesco9, Barbara Antonelli10, Tommaso Maria Manzia11, Amedeo Carraro12, Marco Vivarelli13, Enrico Regalia14, Giovanni Vennarecci15, Nicola Guglielmo16, Manuela Cesaretti17, Alfonso Wolfango Avolio18, Maria Filippa Valentini19, Quirino Lai20, Umberto Baccarani21.
Abstract
There is enough clinical evidence that a T-tube use in biliary reconstruction at adult liver transplantation (LT) does not significantly modify the risk of biliary stricture/leak, and it may even sustain infective and metabolic complications. Thus, the policy on T-tube use has been globally changing, with progressive application of more restrictive selection criteria. However, there are no currently standardized indications in such change, and many LT Centers rely only on own experience and routine. A nation-wide survey was conducted among all the 20 Italian adult LT Centers to investigate the current policy on T-tube use. It was found that 20% of Centers completely discontinued the T-tube use, while 25% Centers used it routinely in all LT cases. The remaining 55% of Centers applied a selective policy, based on criteria of technical complexity of biliary reconstruction (72.7%), followed by low-quality graft (63.6%) and high-risk recipient (36.4%). A T-tube use > 50% of annual caseload was not associated with high-volume Center status (> 70 LT per year), an active pediatric or living-donor transplant program, or use of DCD grafts. Only 10/20 (50%) Centers identified T-tube as a potential risk factor for complications other than biliary stricture/leak. In these cases, the suspected pathogenic mechanism comprised bacterial colonization (70%), malabsorption (70%), interruption of the entero-hepatic bile-acid cycle (50%), biliary inflammation due to an indwelling catheter (40%) and gut microbiota changes (40%). In conclusion, the prevalence of T-tube use among the Italian LT Centers is still relatively high, compared to the European trend (33%), and the potential detrimental effect of T-tube, beyond biliary stricture/leak, seems to be somehow underestimated.Entities:
Keywords: Bile acids; Biliary complications; Survey; T-tube
Mesh:
Year: 2021 PMID: 33792888 PMCID: PMC8397659 DOI: 10.1007/s13304-021-01019-1
Source DB: PubMed Journal: Updates Surg ISSN: 2038-131X
A copy of the original questionnaire used in the survey
| 1) How many adult LT procedures were performed in 2019 in your Center? | |
| 2) Is a pediatric liver transplantation program active in your Center? | - Yes - No |
| 3) Is a living-donor liver transplantation program active in you Center? | - Yes - No |
| 4) Are grafts form donations after circulatory death (DCD) transplanted in your Center? | - Yes - No |
| 5) Does the policy of your Center include the potential use of a T-tube in biliary reconstruction at LT? | - Yes (please go to section IIA) - No (please go to section IIB) |
| 6) Which indications are applied in your Center for the use of a T-tube in deceased donor adult liver transplantation? (more than one option is possible) | - No selective criteria, routine use - Split liver - Advanced donor age - Prolonged cold ischemia time - DCD grafts - Pre-donation acute liver injury (high transaminases levels) - Significant liver steatosis - Size discrepancy of bile ducts between donor and recipients - Small bile duct caliber - Re-transplantation - Delayed biliary reconstruction - High MELD recipient - Others—please specify |
| 7) Has the policy of your Center changed in the last 5 years? | - No - Yes—please specify |
| 8) In how many cases a T-tube was placed at transplantation in your Center, in 2019? | |
| 9) Which are the criteria for T-tube clamping? (more than one option is possible) | - Negative trans-T-tube cholangiography - Low bilirubin serum levels - High bile output |
| 10) In an uneventful LT case, when is T-tube routinely clamped? (postoperative day) | |
| 11) Is the T-tube removed under endoscopic retrograde cholangiopancreatography (ERCP) control? | - Always - Never - Selectively: please specify |
| 12) Is internal biliary stent, instead of T-tube, used in your Center? | - Never - Always - Occasionally - Selectively: please specify |
| 13) In case of T-tube use, is there any protocol for bile replacement in your Center? | - No - Yes—please specify |
| 14) Is ursodexocholic acid routinely administered to the recipient in the postoperative period? | - Always - Never - Selectively: please specify |
| 15) Do you think the T-tube use may represent an hazard for postoperative morbidity other than mechanical biliary complications (leaks, strictures)? | - Yes - No |
| 16) If yes, which pathogenic mechanisms may be implicated? | - Biliary inflammation due to an indwelling catheter - Bacterial colonization - Gut microbiota changes - Malabsorption - Interruption of the entero-hepatic bile-acid cycle - Other: please specify |
| A) When did your Center opted for a no-T-tube policy? | - Less than 5 years ago - Between 5 and 10 years ago - More than 10 years ago |
| B) Which was the rationale that supported this policy change? | |
| C) Is any other mechanical support used in biliary reconstruction at LT? | - No, biliary reconstruction is always performed with duct-to-duct direct anastomosis or hepatico-jenjunostomy - Yes: please specify |
| 14) Is ursodexocholic acid routinely administered to the recipient in the postoperative period? | - Always - Never - Selectively: please specify |
| 15) Do you think the T-tube use may represent an hazard for postoperative morbidity other than mechanical biliary complications (leaks, strictures)? | - Yes - No |
| 16) If yes, which pathogenic mechanisms may be implicated? | - Biliary inflammation due to an indwelling catheter - Bacterial colonization - Gut microbiota changes - Malabsorption - Interruption of the entero-hepatic bile-acid cycle - Other: please specify |
Fig. 1Graphic presentation of answers to question 5 (a) and 6 (b). DCD donation after circulatory death, MELD model for end stage liver disease
Fig. 2Graphic presentation of answers to question 9 (a) and 10 (b). POD postoperative day